Tao Hongyan, Han Zhibo, Han Zhong Chao, Li Zongjin
Department of Pathophysiology, Nankai University School of Medicine, Tianjin 300071, China; The Key Laboratory of Bioactive Materials, Ministry of Education, Nankai University College of Life Science, Tianjin 300071, China.
State Key Lab of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
Stem Cells Int. 2016;2016:1314709. doi: 10.1155/2016/1314709. Epub 2016 Jan 6.
Mesenchymal stem cells (MSCs) have shown their therapeutic potency for treatment of cardiovascular diseases owing to their low immunogenicity, ease of isolation and expansion, and multipotency. As multipotent progenitors, MSCs have revealed their ability to differentiate into various cell types and could promote endogenous angiogenesis via microenvironmental modulation. Studies on cardiovascular diseases have demonstrated that transplanted MSCs could engraft at the injured sites and differentiate into cardiomyocytes and endothelial cells as well. Accordingly, several clinical trials using MSCs have been performed and revealed that MSCs may improve relevant clinical parameters in patients with vascular diseases. To fully comprehend the characteristics of MSCs, understanding their intrinsic property and associated modulations in tuning their behaviors as well as functions is indispensable for future clinical translation of MSC therapy. This review will focus on recent progresses on endothelial differentiation and potential clinical application of MSCs, with emphasis on therapeutic angiogenesis for treatment of cardiovascular diseases.
间充质干细胞（MSCs）因其低免疫原性、易于分离和扩增以及多能性，已显示出其在治疗心血管疾病方面的治疗潜力。作为多能祖细胞，MSCs已展现出分化为各种细胞类型的能力，并可通过微环境调节促进内源性血管生成。对心血管疾病的研究表明，移植的MSCs能够在损伤部位植入，并分化为心肌细胞和内皮细胞。因此，已经开展了多项使用MSCs的临床试验，结果显示MSCs可能改善血管疾病患者的相关临床参数。为了全面理解MSCs的特性，了解其内在特性以及在调节其行为和功能方面的相关调控对于MSCs治疗的未来临床转化不可或缺。本综述将聚焦于MSCs内皮分化的最新进展及其潜在的临床应用，重点是用于治疗心血管疾病的治疗性血管生成。
